Abstract Body

SARS-COV2 has infected more than 62 million people world-wide and led to almost 1.5 million deaths. Exacerbated inflammation, lymphopenia and coagulopathy are part of the complex cascade of events that can lead to death. Additionally, elevated B cells, antibody production and heightened IL-10 levels were associated with severe disease.

We performed scRNAseq/CITEseq on matched peripheral blood mononuclear cells (PBMCs) and bronchoalveolar lavage (BAL) from 5 COVID-19 positive donors with different disease outcomes at time of hospitalization. B cell gene signatures and cytokine/chemokine levels in plasma and BAL fluid (BALF) were associated to live neutralizing antibodies (NAbs) as well as to viral load (VL) readouts.

Fourteen clusters of B cells were identified in PBMCs. They included subsets of naïve, memory B cells and plasmablasts. Ten clusters, comprising mature/effector B cells, were found in BAL while no naïve B cells were observed. Titers of NAbs in the BALF were significantly associated to memory B cell frequencies and were inversely correlated to VL. Systemic NAbs reflected Nabs titers in the BALF, supporting that antibody production in the site of infection impacted the circulating levels of Abs. Peripheral B cells were enriched in signatures associated to chemokine signaling which was positively correlated to the chemokines measured in BALF. This suggests that mature B cells in PBMCs could migrate from periphery to the lung to counteract infection. Importantly, B cells in COVID19 patients presented a strong inflammatory signature that included heightened levels of interferons and IL-10 signaling, the latter a marker of disease severity known to promote B cell differentiation and antibody production.

While this work corroborates prior findings in the literature, it associates IL10 levels and B cell migration to disease severity. A detailed analysis of the antibody repertoire and B cell clonality induced upon infection is under way and would support the understanding of the role of B cells in SARS-COV-2 pathogenesis and also lead to possible immune interventions to counteract severity.